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Infantile neuronal ceroid lipofuscinosis (INCL, or CLN1 disease) is an
inherited neurodegenerative storage disorder caused by a deficiency
of the lysosomal enzyme palmitoyl protein thioesterase 1 (PPT1). It
was widely believed that the pathology associated with INCL was
limited to the brain, but we have now found unexpectedly profound
pathology in the human INCL spinal cord. Similar pathological changes
also occur at every level of the spinal cord of PPT1-deficient (Ppt1−/−)
mice before the onset of neuropathology in the brain. Various
forebrain-directed gene therapy approaches have only had limited
success in Ppt1−/− mice. Targeting the spinal cord via intrathecal ad-
ministration of an adeno-associated virus (AAV) gene transfer vector
significantly prevented pathology and produced significant improve-
ments in life span and motor function in Ppt1−/− mice. Surprisingly,
forebrain-directed gene therapy resulted in essentially no PPT1 activity
in the spinal cord, and vice versa. This leads to a reciprocal pattern of
histological correction in the respective tissues when comparing in-
tracranial with intrathecal injections. However, the characteristic path-
ological features of INCL were almost completely absent in both the
brain and spinal cord when intracranial and intrathecal injections of
the same AAV vector were combined. Targeting both the brain and
spinal cord also produced dramatic and synergistic improvements in
motor function with an unprecedented increase in life span. These
data show that spinal cord pathology significantly contributes to the
clinical progression of INCL and can be effectively targeted therapeu-
tically. This has important implications for the delivery of therapies in
INCL, and potentially in other similar disorders.
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The neuronal ceroid lipofuscinoses (NCLs) are monogenic,predominantly autosomal-recessive, and progressive neurode-
generative lysosomal storage disorders (LSDs), which mainly pre-
sent in childhood. Collectively, the NCLs are the most common
inherited neurological disease of children (1). Because no effective
treatments are currently available, all forms of NCL are fatal (2, 3).
Classic CLN1 disease or infantile NCL (INCL) is caused by
autosomal-recessive mutations in the PPT1 gene (4, 5). This en-
codes palmitoyl protein thioesterase 1 (PPT1), a lysosomal enzyme
that catalyzes the cleavage of thioester bonds linking long-chain
fatty acids to proteins (6, 7). CLN1 disease is a very severe and
rapidly progressing form of NCL, presenting as early as 6 to 24 mo
of age. Affected children display a rapid loss of motor function,
visual acuity, and cognitive abilities and a greatly reduced life ex-
pectancy of between 9 and 13 y (8, 9).
PPT1-deficient mice (Ppt1−/−) exhibit a CLN1 disease-like
phenotype including retinal dysfunction, progressive sensorimotor
defects, seizures, and a shortened life span (10–12). These mice
have been a powerful tool to study functional deficits, as well as
pathology, in the forebrain and cerebellum. The brains of Ppt1−/−
mice showed reduced brain volume (13), progressive cerebral at-
rophy, and regional neuron loss, all preceded by glial activation
(11, 14). Neurons also showed the characteristic accumulation of
autofluorescent storage material (AFSM) within their cell bodies
(11). Similar reactive and degenerative changes occur in the cer-
ebellum (15), and there is evidence for both axonal and synaptic
pathology (16). However, these findings cannot fully explain the
sensorimotor deficits observed both in patients and Ppt1−/− mice
(17, 18).
Various experimental therapies have been tested to treat fore-
brain pathology in Ppt1−/− mice, including antioxidants (19, 20),
enzyme replacement therapy (ERT) (21, 22), human neuronal
stem cells (23), and forebrain-directed gene therapy (12, 24–27).
Of these, adeno-associated virus (AAV) vector-mediated gene
transfer has been the most promising (3, 28). However, these
therapies have met with only limited success, especially compared
with efforts in CLN2 disease, another form of NCL caused by a
lysosomal enzyme deficiency (29, 30).
To investigate an anatomical basis for the sensorimotor deficits
seen in Ppt1−/− mice and to explain the relatively poor efficacy of
forebrain-targeted therapies, we postulated the existence of neu-
ropathology outside the brain. We focused our analysis on the
spinal cord as a key component of the sensory and motor pathways.
Although the spinal cord has not previously been characterized in
detail in any form of NCL, our recent analysis of intrathecally de-
livered enzyme replacement therapy had revealed significant end-
stage pathology in the spinal cords of Ppt1−/− mice (31). This
prompted us to investigate the onset and progression of this spinal
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pathology and how it relates to the well-defined sequence of events
in the forebrain of these mice. This novel temporal analysis revealed
unexpectedly early and profound neuropathological changes that
occur at all levels of the cord of Ppt1−/−mice. These changes started
at an age when there were few neurodegenerative changes seen in
the brains of these mice. Crucially, similar pathology was also pre-
sent in human CLN1 spinal cord autopsy material.
This novel finding of early and profound pathology throughout
the spinal cord led us to investigate whether it was possible to
target this region therapeutically by means of AAV-mediated gene
therapy using a third-generation AAV2/9 vector (32, 33). There-
fore, we tested whether intrathecal (IT) injections of an AAV2/9-
hPPT1 vector, either alone or in combination with intracranial
(IC) injections (12, 24–27), would have any beneficial effect on
disease progression and brain and spinal cord pathology.
Results
Human CLN1 Spinal Cord Displays Profound Neuropathological Changes.
To investigate whether similar pathological changes occur in the
spinal cord of human CLN1 disease as those found in the brain
Fig. 1. Spinal cord pathology in human and murine CLN1 disease. (A) Representative bright-field images of ventral horns (demarcated by the dotted lines) of
human thoracic spinal cord showing fewer, more darkly stained neurons (Nissl), an increase in the number of hypertrophied microglia (CD68), and representative
confocal microscopy images showing pronounced accumulation of autofluorescent storage material in human post mortem CLN1 disease tissue comparedwith an
unaffected control. [Scale bars, 200 μm (bright field, Left and Center), 100 μm (confocal, Right), and 25 μm (Insets).] (Insets) Selected from corresponding lower-
power views. (B) Unbiased optical fractionator counts reveal significant loss of Nissl (cresyl fast violet)-stained neurons in the dorsal and ventral horns of the spinal
cords of PPT1-deficient (red bars) mice as early as 3 mo of age, compared with age-matched wild-type controls (blue bars). Dots represent scatterplots of individual
animals. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, two-tailed, unpaired parametric t test. Values are shown as mean ± SEM (n = 5 mice per group).
(C) Representative confocal microscopy images of unstained sections showing the progressive accumulation of autofluorescent storage material (green) within
morphologically identified neuronal cell bodies in the ventral horns (represented by the dotted lines) of the lumbosacral cord of Ppt1−/− mice as early as 3 mo,
compared with age-matched wild-type controls. [Scale bars, 100 μm and 25 μm (Insets).] (Insets) Selected from corresponding lower-power views.

















(34), we obtained spinal cord sections from a single 6-y-old dis-
eased case and a 10-y-old neurologically normal spinal cord. Nissl
staining revealed fewer neurons present in human CLN1 tissue,
and those that persisted displayed a range of abnormal morphol-
ogies, being either distended by accumulated storage material or
darkened and shrunken (Fig. 1A). CD68 staining for microglia
revealed the presence of many darkly stained and hypertrophied
microglia in the CLN1 disease case (Fig. 1A). These activated
microglia were predominantly within the gray matter, but were also
present in white matter tracts. As expected, the few remaining
neurons displayed massive amounts of autofluorescent storage
material (Fig. 1A). In addition, many smaller cells, morphologically
identified as microglia, also displayed pronounced levels of storage
material. These changes reveal that pronounced neuropathological
changes occur in the spinal cord in this disorder. This unexpected
finding led us to systematically investigate the temporal and spatial
progression of spinal pathology in Ppt1−/− mice.
Early and Widespread Neuron Loss in Ppt1−/− Mouse Spinal Cords.
Pronounced neuron loss is an important feature of CLN1 dis-
ease, and becomes significant within the cerebellum and thala-
mus of Ppt1−/− mice by 5 mo (14, 15). We obtained unbiased
optical fractionator counts of Nissl-stained neurons in the dorsal
and ventral horns, at all levels of the spinal cord of control and
Ppt1−/− mice at different ages. These data revealed a significant
loss of neurons at all three levels (cervical, lumbosacral dorsal
horn, and thoracic ventral horn) of the cord, sometimes as early
as 3 mo (Fig. 1B). Regardless of rostrocaudal level, there was
invariably a significant loss of neurons both in the dorsal and
ventral horns in Ppt1−/− mice from 5 mo of age onward. There
was also significant neuron loss at 3 mo of age in both the dorsal
and ventral horns, indicating an earlier onset of neurodegener-
ative changes in the spinal cord compared with the brain (14).
Progressive Accumulation of Autofluorescent Storage Material in
Ppt1−/− Mouse Spinal Cords. Progressive accumulation of AFSM
within cell bodies is pathognomic of the NCLs (1, 9). This provides
a useful diagnostic readout of the extent of pathology. In Ppt1−/−
mice, the characteristic punctate appearance of this auto-
fluorescent storage material was already evident at 3 mo in the cell
bodies within spinal gray matter of the dorsal and ventral horns,
and occurred to a similar extent at all levels (Fig. 1C).
Ppt1−/− Mouse Spinal Cords Show Progressive Glial Activation at All
Levels. Astrocytosis and microglial activation are closely associated
with neuron loss in the forebrains of Ppt1−/− mice, typically pre-
ceding neurodegeneration (14). Immunostaining sections of cervi-
cal, thoracic, and lumbar cord for CD68 (typically used as a marker
of microglial activation by revealing the associated changes in
microglial morphology and increased staining intensity) and glial
fibrillary associated protein (GFAP; typically used as a marker of
astrocytosis by revealing the associated changes in astrocyte mor-
phology and increased staining intensity) (Fig. 2) revealed a pro-
found and early-onset glial activation at all levels of the Ppt1−/−
spinal cord. From 3 mo onward, Ppt1−/− mice displayed a dramatic
increase in the intensity of CD68 staining (Fig. 2A), with many
more of these cells displaying the typical hypertrophied morphol-
ogy of brain macrophages. Although most pronounced throughout
the gray matter, increasingly more intensely stained and hyper-
trophied microglia were also present in the Ppt1−/− spinal white
matter from 5 mo onward. This white matter microgliosis appeared
more pronounced in the dorsal compared with the ventral funiculi,
but was present at all rostrocaudal levels of the Ppt1−/− spinal cord
(Fig. 2A). Both wild-type and Ppt1−/−mice exhibited intense GFAP
staining of fibrous astrocytes within all white matter tracts at all
ages examined. From 3 mo of age onward in the Ppt1−/− mouse
spinal cord, numerous intensely GFAP-stained astrocytes with
hypertrophied cell bodies and relatively few thickened processes
were present throughout the spinal gray matter, with no obvious
laminar specificity. From 5 mo onward, the entire spinal gray
matter of Ppt1−/− mice was completely filled with highly activated
astrocytes (Fig. 2B).
Intracranial and Intrathecal Injections of AAV2/9-hPPT1 Deliver PPT1
Activity to the Brain and Spinal Cord, Respectively. To determine
whether this spinal cord disease could be effectively targeted
therapeutically, Ppt1−/− mice were injected intrathecally with an
AAV vector (IT-AAV2/9-hPPT1) to target the cord, intracranially
(IC-AAV2/9-hPPT1) to target the brain, or a combination of the
two delivery routes (IC/IT-AAV2/9-hPPT1). At 1 mo of age,
supraphysiological levels of PPT1 activity were detected in the
spinal cords of mice receiving IT-AAV2/9-hPPT1 alone (Fig. 3A),
whereas the brains of these intrathecally treated mice had only
∼10% of normal levels. A reciprocal pattern of enzyme activity
was seen in PPT1-deficient mice injected solely with IC-AAV2/
9-hPPT1, where these mice had supraphysiological or WT
levels of PPT1 activity in their brains but nearly undetectable
levels of PPT1 activity in their spinal cords (Fig. 3A).
To determine whether this viral-mediated expression was
persistent, PPT1 activity was measured in 7-mo-old mouse
brains (Fig. 3B). PPT1 activity was virtually undetectable in the
brains of untreated Ppt1−/− mice compared with wild-type mice.
There was ∼2 to 5% of wild-type PPT1 activity in the brains of
mice receiving IT-AAV2/9-hPPT1 (Fig. 3B). There was no signifi-
cant difference between IC-AAV2/9-hPPT1–only and IC/IT-AAV2/
9-hPPT1 combination-treated PPT1 brain activities compared with
WT at all of the time points examined (3, 5, 7, and 9 mo; Fig. 3B
and Fig. S1A). Similar results were observed when mice from
these treatment groups were stained using a recently developed
Fig. 2. Ppt1−/− mouse spinal cord shows progressive glial activation at all
levels. Representative bright-field microscopy images of the spinal cords of
Ppt1−/− and wild-type control mice reveal the increased abundance, hyper-
trophy, and increased staining intensity of CD68-positive microglia (A) and
GFAP-positive astrocytes (B) in mutant mice as early as 3 mo of age at all levels
of the spinal cord. This glial activation progressively increases with age. The
dotted lines demarcate the boundary between the gray and white matter.
[Scale bars, 200 μm and 25 μm (Insets).] (Insets) Selected from corresponding
lower-power views.
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histochemical stain for PPT1 (35) [Figs. S2 (forebrain) and S3
(spinal cord)].
A reduction in the secondary elevation of other lysosomal en-
zymes serves as a biochemical surrogate of therapeutic efficacy in
PPT1-deficient mice (24). At 7 mo of age, there was a significant
increase in brain β-glucuronidase (GUSB) activity in untreated
Ppt1−/− mice (Fig. 3C). This secondary elevation of GUSB activity
persisted in the brains of PPT1-deficient mice receiving IT-AAV2/
9 alone. However, there was a significant decrease in brain GUSB
activity in mice receiving either IC-AAV2/9-hPPT1 alone or IC/IT-
AAV2/9-hPPT1 combined treatment (Fig. 3C). Brain GUSB activity
was not significantly different betweenWT, IC-AAV2/9-hPPT1–only,
and IC/IT-AAV2/9-hPPT1 combination-treated mice at 7 mo. As
with PPT1 activity, these patterns of GUSB activity were consistent
across every time point examined (3, 5, 7, and 9 mo; Fig. S1B).
Combination IC/IT-AAV2/9-hPPT1 Gene Therapy Synergistically Improves
Life Span and Prolongs Motor Function in Ppt1−/− Mice. All treatment
groups showed a significant increase in median life span compared
with untreated Ppt1−/−mice (∼8.4 mo). Combination IC/IT-AAV2/
9-hPPT1–treated mice had the longest median life span of 19.3 mo,
with the longest-lived mouse at 22 mo, compared with IC-AAV2/9-
hPPT1–injected mice (median 13.6 mo) or IT-AAV2/9-hPPT1–
injected mice (median 11.8 mo) (Fig. 4A). Rotarod testing revealed
that IC/IT-AAV2/9-hPPT1 mice performed better for much
longer than either IC-AAV2/9-hPPT1 or IT-AAV2/9-hPPT1 mice
(Fig. 4B). However, all treated animals performed better than
their untreated counterparts from 7 mo on (Fig. 4B). At 5 mo of
age, when there is significant pathology in both the brain and
spinal cord, there was no evidence of a learning deficit during the
training/acclimation phase of the rotarod test in any group.
AAV2/9-Mediated Gene Therapy Rescues Cortical Atrophy and Delays
Neuron Loss in Ppt1−/− Mice. Profound brain atrophy is a hallmark
of CLN1 disease (11, 13, 14), and cortical thickness (Fig. 4C) and
brain weight (Fig. 4D) were measured as indicators of this process.
There was a significant thinning of the cerebral cortex in untreated
Ppt1−/− and IT-AAV2/9-hPPT1–treated mice compared with wild-
type controls. However, cortical thinning was effectively halted in
IC-AAV2/9-hPPT1– and IC/IT-AAV2/9-hPPT1–treated mutant
mice (Fig. 4C). The weight of the Ppt1−/− mouse brain gradually
decreases with disease progression (11, 14). The decrease in brain
weight of mice treated with IT-AAV2/9-hPPT1 was similar to that
seen in untreated Ppt1−/− mice in both magnitude and rate (Fig.
4D). Brain weight was maintained at nearly normal levels in both
the IC-AAV2/9-hPPT1 alone and IC/IT-AAV2/9-hPPT1 combi-
nation treatment groups for up to 9 mo (Fig. 4D).
Severe and progressive neuron loss is another hallmark of
CLN1 disease (14, 15). Consistent with these previous observations,
there was a significant and progressive loss of neurons in the primary
motor cortex (M1), ventral posterior thalamic nuclei (VPM/VPL),
and ventral horn of the lumbosacral spinal cord (LSC) of untreated
Ppt1−/− mice (Fig. 4E). All treatment groups showed significant
improvements in M1 cortical neuron counts at 3 and 7 mo (Fig. 4E).
The VPM/VPL are more severely affected in Ppt1−/− mice (11, 14),
and neuron loss in this region was broadly comparable in all treat-
ment groups to that observed in untreated Ppt1−/−mice regardless of
age (Fig. 4E). However, the neuron loss in the LSC at 7 mo of age
was significantly less in the IT-AAV2/9-hPPT1–only and IC/IT-
AAV2/9-hPPT1 combination treatment groups compared with un-
treated Ppt1−/− mice. At 9 mo of age, when all untreated Ppt1−/−
mice had already died, there was no significant difference in LSC
neuron counts between WT controls and the IC/IT-AAV2/9-
hPPT1–treated Ppt1−/−mice (Fig. S4A). These data show that AAV-
mediated gene therapy had a significant neuroprotective effect in
the regions where it was targeted in Ppt1−/− mice.
IC and IT Delivery of Gene Therapy Differentially Reduce AFSM in the
Brains and Spinal Cords of Ppt1−/− Mice. As expected, there was an
increase in AFSM at every age examined in all regions of untreated
Ppt1−/− brains compared with WT controls (Fig. 5A). In the
M1 cortex, both IC-AAV2/9-hPPT1– and IC/IT-AAV2/9-hPPT1–
treated mice showed reduced AFSM levels, but these did not reach
statistical significance, compared with IT-AAV2/9-hPPT1 mice
(Fig. 5B). Although all treatment groups showed levels of AFSM
accumulation that were higher than wild-type controls, this was
much lower than in untreated Ppt1−/− mice. In the VPM/VPL, all
of the treatment groups had an apparent decrease in AFSM at
3 and 5 mo compared with untreated Ppt1−/− mice (Fig. 5A). At
5 and 7 mo, IC-AAV2/9-hPPT1– and IC/IT-AAV2/9-hPPT1–
treated mice appeared to have the greatest decrease in AFSM in
the VPM/VPL (Fig. 5A), but this was not statistically significant
(Fig. 5B). In the lumbar spinal cord, both IC/IT-AAV2/9-hPPT1 and
IT-AAV2/9-hPPT1 mice showed AFSM levels comparable to wild-
type controls, whereas IC-AAV2/9-hPPT1 mice showed similar
amounts of AFSM accumulation to untreated Ppt1−/− mice (Fig. 5).
At 9 mo, only IT-AAV2/9-hPPT1 and IC-AAV2/9-hPPT1 mice
showed a significantly higher level of AFSM compared with the
wild type in the M1 cortex and lumbar spinal cord, respectively
(Fig. S4B).
Combination IC/IT-AAV2/9 Gene Therapy Reduces Neuroinflammation
in Ppt1−/− Mice. Progressive microglial activation and astrocytosis
are prominent features of CLN1 disease, and can be quantified by
thresholding image analysis (11, 14). As before (Fig. 2), untreated
Ppt1−/− mice showed a significant increase in CD68 and GFAP
staining in the brain and lumbosacral spinal cord compared with
wild-type mice at every time point (Figs. 6A and 7A). This was
confirmed by thresholding image analysis (Figs. 6B and 7B). In the
brains of mice treated with IC-AAV2/9-hPPT1 alone or the IC/IT-
AAV2/9-hPPT1 combination, there was an apparent decrease in
CD68 and GFAP staining in the M1 cortex at every time point
(Figs. 6 and 7 and Fig. S5). There was also a moderate decrease in
CD68 staining in the M1 cortex of mice receiving IT-AAV2/9-
hPPT1 alone at 3 and 5 mo of age, but this decrease was not
sustained at 7 mo (Fig. 6B). There was a significant impact upon
Fig. 3. Changes in PPT1 and secondary enzyme activity in regions targeted
with AAV2/9-mediated gene therapy. There were reciprocal increases in PPT1
activity between intrathecally (IT-AAV2/9) and intracranially (IC-AAV2/9) in-
jected mice in the spinal cord and brain, respectively, at 1 mo (A). PPT1 levels in
the brains of wild-type and IC-AAV2/9–injected mice were significantly in-
creased compared with Ppt1−/−, whereas IT-AAV2/9–injected mice showed
significantly elevated levels of PPT1 in the spinal cord. At 7 mo, the brains of IC-
AAV2/9 and combination-treated mice (IC/IT-AAV2/9) show significant in-
creases in PPT1 activity (B) and significant decreases in β-glucuronidase
activity (C), similar to WT mice, compared with Ppt1−/− mice. Dots represent
scatterplots of individual animals. *P < 0.05, **P < 0.01, ***P < 0.001, one-
way ANOVA with post hoc Bonferroni correction. Values shown are mean ±
SEM (n = 3 mice per group).

















CD68 staining in the thalamus of IC-AAV2/9-hPPT1–treated
mice at 5 and 7 mo and for IC/IT-AAV2/9-hPPT1 mice at 5 mo
(Fig. 6). In contrast, there was no significantly lower GFAP
staining across any of the treatment groups in the thalamus re-
gardless of age (Fig. 7). In the lumbosacral cord of mutant mice
treated with IT-AAV2/9-hPPT1 or IC/IT-AAV2/9-hPPT1 at 3, 5,
and 7 mo, there appeared to be a dramatic decrease in both CD68
and GFAP staining (Figs. 6 and 7), with accompanying effects on
the morphological appearance of these microglia (Fig. 6A). Mutant
mice treated with IC-AAV2/9-hPPT1 alone also had decreased
CD68 staining in the lumbosacral spinal cord at 3 mo of age but
not at 5 or 7 mo (Fig. 6B). There was no decrease in GFAP
staining in the lumbosacral spinal cord at any age following IC-
AAV2/9-hPPT1 only (Fig. 7). At 9 mo, IC-AAV2/9-hPPT1–treated
mice showed a significant increase in CD68 staining in the thala-
mus and LSC, as well as a significant increase of GFAP staining in
Fig. 4. Targeted AAV2/9-mediated gene therapy delays disease progression and prevents neuron loss. (A) Kaplan–Meier survival curve showing that the median
life span for combination IC/IT-treated mice (IC/IT-AAV2/9) (blue) is significantly greater than either intrathecally (IT-AAV2/9) (yellow) or intracranially (IC-AAV2/9) treated
mice (green) (n = 10 mice per group). Analysis by log-rank test for trend was significant for overall survival (P < 0.0001). Individual comparisons between curves, using
Bonferroni correction for multiple comparisons, were each significant (***P < 0.001) for each group compared with the wild type, as well as between intrathecally
(IT-AAV2/9) and intracranially (IC-AAV2/9) treated mice (###P < 0.001). (B) Constant-speed rotarod test revealed that untreated Ppt1−/−mice (red) were unable to stay on
the rotarod past 7 mo, intrathecally (IT-AAV2/9) treated mice (yellow) could not stay on the rotarod past 11 mo, intracranially (IC-AAV2/9) treated mice (green) could not
stay on the rotarod past 13 mo, and combination IC/IT-treated mice (IC/IT-AAV2/9) (blue) showed deficits at 15 mo and could not stay on the rotarod past 19 mo.
Statistical significance for each group compared with wild-type mice (*P < 0.05, ***P < 0.001), and compared between intrathecally (IT-AAV2/9) and intracranially
(IC-AAV2/9) treated mice (###P < 0.001), two-way repeated-measure ANOVA (n = 10 mice per group). (C) Representative images of cortices from treated animals in Nissl
(cresyl fast violet)-stained sections showing near–wild-type thickness of IC-AAV-2/9– and IC/IT-AAV2/9–treatedmouse cortices but not in IT-AAV2/9–treatedmice. (D) Brain
weights for IC-AAV2/9– and IC/IT-AAV2/9–treated mice were essentially the same as WT mice at all time points examined. However, IT-AAV2/9–treated and untreated
Ppt1−/−mice showed a significant reduction in brainweight comparedwithWT brain weight at 7 and 9mo. Dots represent scatterplots of individual animals. Significance
is compared with wild-type mice (***P < 0.001, ****P < 0.0001), and compared between intrathecally (IT-AAV2/9) and intracranially (IC-AAV2/9) treatedmice (##P < 0.01,
###P < 0.001), two-way repeated-measure ANOVA (n = 3 mice per group). (E) Unbiased optical fractionator counts of Nissl (cresyl fast violet)-stained neurons at 3, 5, and
7 mo post injection in the M1 motor cortex, VPM/VPL of the thalamus, and ventral horn (VH) of the lumbar spinal cord show that targeted AAV-2/9–mediated gene
therapy has a neuroprotective effect. Significance is compared with untreated WT mice at all time points. Dots represent scatterplots of individual animals. *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001, one-way ANOVA with post hoc Bonferroni correction. Values shown are mean ± SEM (n = 3 mice per group).
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the thalamus (Fig. S5). Reciprocally, IT-AAV2/9-hPPT1–treated
mice showed significantly higher levels of CD68 and GFAP
staining in the M1 cortex and VPM/VPL. However, IC/IT-AAV2/
9-hPPT1–treated mice did not show any significant change from
WTmouse levels of CD68 or GFAP staining, with the exception of
GFAP staining in the VPM/VPL (Fig. S5).
Cytokine and chemokine levels in whole-brain homogenates of
treated mice and controls were measured as a complementary in-
dicator of neuroinflammation (36, 37). At 7 mo of age, there were
no significant differences in the levels of tumor necrosis factor α
(TNF-α) or IFN-γ between any of the control or treatment groups
(Fig. 8A). For both the CXC-motif and CCL-motif chemokines,
there was a significant increase in untreated Ppt1−/− brains com-
pared with wild-type brains. Neither IC-AAV2/9-hPPT1– nor IT-
AAV2/9-hPPT1–treated mice showed reduced chemokine levels
below that of untreated Ppt1−/− brains. There was an apparent
increase above Ppt1−/− chemokine levels for IT-AAV2/9-hPPT1
mice in CXCL1, CXCL10, CCL2, and CCL7. However, in the
brains of IC/IT-AAV2/9-hPPT1 combination-treated Ppt1−/− mice,
there was a dramatic and significant decrease in nearly all of the
chemokines measured to near–wild-type levels (Fig. 8 B and C).
These data show that AAV2/9-hPPT1 therapy significantly
reduces neuroinflammation in the region to which it is targeted,
especially in the case of GFAP and CD68 up-regulation. Indeed,
combining IC and IT administration of AAV2/9-hPPT1 therapy
has a powerful synergistic effect upon multiple measures of
disease outcome.
Discussion
The brain has always been considered the main locus of pathology
in CLN1 disease (4, 34, 38). However, compared with promising
data obtained for another form of NCL, CLN2 disease (32, 33, 39),
previous attempts to treat Ppt1−/− mice by targeting the known
Fig. 5. Targeted gene therapy reduces storage material accumulation in
Ppt1−/−mice. (A) Representative confocal microscopy images of treated animals
and controls at 7 mo showing the primary motor cortex, VPM/VPL of the
thalamus, and ventral horn of the lumbar spinal cord with differential patterns
of reduction of autofluorescent storage material accumulation in intracranially
(IC-AAV2/9), intrathecally (IT-AAV2/9), and combination intracranially and in-
trathecally (IC/IT-AAV2/9) treated mice, compared with untreated Ppt1−/− and
wild-type control mice. IC/IT-AAV2/9 mice show an overall greater reduction in
AFSM than either IC-AAV2/9 or IT-AAV2/9 therapy alone. The dotted lines
demarcate the boundary between the gray and white matter in spinal cord
sections. [Scale bars, 100 μm and 25 μm (Insets).] (Insets) Selected from corre-
sponding lower-power views. (B) Thresholding image analysis at 3-, 5-, and 7-
mo time points showing a significant but differential pattern of the reduction
of AFSM accumulation based on the site of vector administration, with IC/IT-
treated mice showing the greatest overall reduction of AFSM. Significance is
compared with untreated Ppt1−/− mice. Dots represent scatterplots of individ-
ual animals. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVAwith post hoc
Bonferroni correction. Values shown are mean ± SEM (n = 3 mice per group).
Fig. 6. Targeted gene therapy reduces microglial activation in Ppt1−/− mice.
(A) Representative images of CD68 staining in treated animals and controls at
7 mo. CD68 staining was examined in the primary motor cortex, VPM/VPL of
the thalamus, and ventral horn of the lumbar spinal cord showing differential
patterns of reduction of microglial activation in intracranially (IC-AAV2/9), in-
trathecally (IT-AAV2/9), and combination intracranially and intrathecally (IC/IT-
AAV2/9) treated mice, compared with untreated Ppt1−/− and wild-type control
mice. IC/IT-AAV2/9 mice showed an overall greater reduction in microglial acti-
vation than either IC-AAV2/9 or IT-AAV2/9 therapy alone. The dotted lines de-
marcate the boundary between the gray and white matter in spinal cord sections.
[Scale bars, 200 μm and 25 μm (Insets).] (Insets) Selected from corresponding
lower-power views. (B) Thresholding image analysis at 3-, 5-, and 7-mo time points
revealed a significant but region-specific pattern in the impact upon microglial
activation based on the site of vector administration, with IC/IT-AAV2/9–treated
mice showing the greatest overall reduction of microglial activation. Significance
is compared with untreated Ppt1−/−mice. Dots represent scatterplots of individual
animals. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA with post hoc
Bonferroni correction. Values shown are mean ± SEM (n = 3 mice per group).

















sites of pathology in the forebrain and cerebellum have had rela-
tively limited success (3, 28). Therefore, we hypothesized the
presence of pathology in other regions of the central nervous
system that were not affected by these treatments. To better un-
derstand the early sensorimotor changes that occur in Ppt1−/−mice
(18), we focused our analysis on the spinal cord, a structure that
has not been seriously considered as a site of pathology in any
major form of NCL (38) but in which we had previously seen
pathology in end-stage PPT1-deficient mice (31). We have ex-
panded upon the original brief description of the cellular pathol-
ogy in the human CLN1 spinal cord (4, 34), and revealed that
pathology in this region is not only more profound than initially
anticipated but also occurs surprisingly early in disease progression
in Ppt1−/− mice. Indeed, the regional atrophy, loss of different
neuron populations, profound glial response, and accumulation of
autofluorescent storage material that occur in the brains of these
mice (11, 13, 14) all occur to a similar extent in the spinal cord, but
at an earlier stage of disease progression. Finding such surprisingly
severe and early-onset pathology in a structure that has been rel-
atively neglected analytically suggested to us that the spinal cord
may significantly contribute to disease progression and would
therefore need to be targeted therapeutically to increase the
chances of a positive outcome.
To further improve the efficacy of gene therapy in Ppt1−/− mice,
we used a third-generation AAV vector (AAV2/9), which is ca-
pable of broader distribution within the parenchyma of the brain
and increased transduction of neuronal lineages compared with
previous generations of AAV vectors (32, 33, 40). Based on a
previous study that showed that intrathecal delivery of recombinant
PPT1 enzyme could minimally improve the disease phenotype of
Ppt1−/− mice (31), we delivered AAV2/9-hPPT1 intrathecally to
target the spinal cord. We also combined this approach with brain-
directed gene therapy (12, 24–27).
Consistent with previous studies, intracranial injection of an
AAV2/9-hPPT1 vector resulted in a significantly increased life
span, a preservation of motor function that we have shown pre-
viously to correlate with improved cerebellar pathology, and de-
creased pathology in the forebrain (12, 24–27). However, there was
almost no improvement in spinal cord pathology following brain-
directed gene therapy in Ppt1−/− mice. Conversely, intrathecal in-
jection of AAV2/9-hPPT1 alone, despite having minimal impact
upon pathology in the brain of these mice, significantly decreased
pathology in the spinal cord, significantly increased life span, and
improved motor function. The differential effects of these treat-
ments are consistent with the reciprocal pattern of enzyme activity
in these brain regions following IT vs. IC injections. Intrathecal
injection resulted in ∼10% normal levels of PPT1 activity in the
brain, and intracranial injections led to ∼5% normal levels of
PPT1 activity in the spinal cord (Fig. 3A). Such enzyme levels might
normally be sufficient to correct the disease phenotype in lyso-
somal storage diseases (41, 42). However, it may be that a higher
Fig. 7. Combination gene therapy reduces astrocytosis in Ppt1−/− mice.
(A) Representative images of GFAP staining in treated animals and controls at
7 mo, examined in the primary motor cortex, VPM/VPL of the thalamus, and
ventral horn of the lumbar spinal cord, showing differential patterns of re-
duction of astrocytosis in intracranially (IC-AAV2/9), intrathecally (IT-AAV2/9),
and combination intracranially and intrathecally (IC/IT-AAV2/9) treated Ppt1−/−
mice, compared with untreated Ppt1−/− andwild-type control mice. IC/IT-AAV2/9
mice showed an overall greater reduction in astrocytosis than either IC-AAV2/9
or IT-AAV2/9 therapy alone. The dotted lines demarcate the boundary be-
tween the gray and white matter in spinal cord sections. [Scale bars, 200 μm
and 25 μm (Insets).] (Insets) Selected from corresponding lower-power views.
(B) Thresholding image analysis at 3-, 5-, and 7-mo time points showing a sig-
nificant but treatment-specific pattern of the reduced astrocytosis based on
the site of vector administration, with IC/IT-AAV2/9–treated mice showing the
greatest overall reduction of astrocytosis. Significance is compared with un-
treated Ppt1−/−mice. Dots represent scatterplots of individual animals. *P < 0.05,
**P < 0.01, ***P < 0.001, one-way ANOVA with post hoc Bonferroni correction.
Values shown are mean ± SEM (n = 3 mice per group).
Fig. 8. Brain cytokine levels in treated animals at 7 mo. (A) The levels of
various cytokines were measured in brain homogenates from treated and
untreatedWT and Ppt1−/− animals. There were no significant differences in the
general proinflammatory cytokines TNF-α [with the exception of intrathecal
(IT-AAV2/9) vs. combination intracranial/intrathecal (IC/IT-AAV2/9)] or IFN-γ
between any of the groups. (B) Analysis of CXC-motif chemokines showed a
significant increase in CXC-motif chemokines in Ppt1−/− and IT-AAV2/9 animals.
IC/IT-AAV2/9 animals had a significant decrease in CXCL1 and CXCL2 at 7 mo.
(C) CC-motif chemokines showed a significant increase in Ppt1−/− and IT-AAV2/9
mice. IC/IT-AAV2/9 animals had significantly decreased levels of CCL2, CCL7, and
CCL5 at 7 mo. Overall, IC/IT-AAV2/9–treated mice showed chemokine levels
similar to wild-type mice. Both CXC- and CC-motif chemokines are monocyte and
leukocyte chemoattractive and activation molecules. Statistical comparisons were
made with untreated Ppt1−/− mice. Values shown are mean ± SEM (n = 3 mice
per group). Dots represent scatterplots of individual animals. *P < 0.05, **P <
0.01, ***P < 0.001, one-way ANOVA with post hoc Bonferroni correction.
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level of PPT1 activity is required to achieve therapeutic benefit in
CLN1 disease, and this may vary between brain regions.
No significant differences in cytokine or chemokine levels were
observed in the brain between the IC-AAV2/9-hPPT1–treated mice
and their untreated Ppt1−/− littermates, even though there was a
decrease in histological markers of inflammation (CD68 and
GFAP). Not surprisingly, there were no decreases in cytokine/
chemokine levels in the brains of IT-AAV2/9-hPPT1–treated mice.
In fact, the levels of MCP-1 and MCP-3 were significantly elevated
in IT-AAV2/9–treated animals compared with untreated Ppt1−/−
mice. Although the reason for this elevation is not clear, it could be
an inflammatory response to the IT injection of virus that exacer-
bates the PPT1-associated neuroinflammation that is not corrected
by IT-AAV2/9 alone. Taken together with the histological data, it
appears that the effects of AAV gene therapy on cytokine/che-
mokine levels are localized to the areas of injection (Fig. 8). Indeed,
in intracranially or intrathecally treated mice, there are clearly
untreated regions of the CNS where the disease is still progressing.
It seems likely that IC-treated animals have decreased cytokine/
chemokine levels in certain areas of the brain. However, the un-
treated regions may still have high levels of cytokines/chemokines
that overwhelm any regional reductions in a bulk sample of tissue.
It is only when both the brain and spinal cord are treated that the
elevated cytokines/chemokines return to nearly normal levels.
The differential clinical response of mice treated with either IC-
AAV2/9 only or IT-AAV2/9 alone provides important insights into
the progression of INCL. Targeting the spinal cord via IT-AAV2/
9-hPPT1 corrected much of the pathology in the spinal cord but
had little effect on the brain. Despite this, motor function was
improved and the life span in these Ppt1−/− mice was significantly
increased, even when histological correction was limited to the
spinal cord. Such data suggest that this spinal pathology is clinically
significant. However, it is unclear whether targeting the spinal cord
also corrected other, yet unknown aspects of CLN1 disease such as
any possible dorsal root ganglion (DRG) or peripheral nervous
system pathology.
Our data suggest that although CLN1 disease significantly im-
pacts the spinal cord, the brain remains the most severely and
acutely affected region of the CNS in Ppt1−/−mice. Indeed, limiting
therapy to the brain alone is clearly more effective than targeting
the spinal cord alone. This study also clearly demonstrates that
targeting the cerebral cortex, hippocampus, cerebellum, and spinal
cord is not sufficient to correct the entire brain. As shown in this
study, the thalamus is only partially corrected even when the brain
and spinal cord are simultaneously targeted. It is likely that tar-
geting the thalamus directly could further increase efficacy because
it is a site of significant disease and it is the first region of the brain
to be affected in CLN1 disease (14). Indeed, the thalamus con-
sistently appears to be an important and early disease focus in
many different LSDs, as is revealed by T2 imaging of these patients
(43), and pronounced thalamic pathology has been shown in
mouse models of all forms of NCL (reviewed in ref. 44) and all
other LSDs we have examined (e.g., 45, 46). As such, it will be
important to direct therapies to this brain region, and this may be
key for improving therapeutic outcome further.
Combining intracranial and intrathecal injections of AAV2/9-
hPPT1 led to dramatic and significant extension in life span and
improvement in motor function compared with either therapy
alone in Ppt1−/−mice. Indeed, IC/IT-AAV2/9-hPPT1–treated mice
display the greatest biochemical, histological, and clinical im-
provements ever reported in CLN1 mice by a considerable margin.
This is most likely due to the broader distribution of the AAV2/9-
hPPT1 vector (and PPT1 enzyme levels) in the CNS. Taken to-
gether, these data suggest that it will be necessary to treat both the
spinal cord and brain to achieve maximum efficacy. Interestingly,
these data also show that targeting both the brain and spinal cord
results in synergistic improvements. For example, if the modalities
were simply additive, the predicted median life span would be
∼16.7 mo rather than the ∼19.3 mo observed. The similar im-
provement in motor function also suggests a synergistic effect,
where the age at which the combination therapy mice begin to fall
off the rotarod is greater than the sum of the increases observed
with either intracranial or intrathecal treatment alone.
Although the combination therapy can dramatically and signif-
icantly increase life span and improve motor function, the IC/IT-
AAV2/9-hPPT1–treated mice still have a reduced life span com-
pared with their wild-type littermates, suggesting that these mice
may be succumbing either to the residual pathology in regions of
the CNS such as the thalamus or to disease outside of the central
nervous system. There is a growing body of evidence for cardiac
dysfunction (47–49) as well as systemic metabolic defects (50, 51)
in CLN1 disease and other models of NCL. Targeting such addi-
tional sites of pathology and secondary disease mechanisms using
other therapeutic modalities such as small-molecule drugs or
recombinant PPT1 may further extend the life span and improve
the quality of life for CLN1 disease patients.
This study clearly demonstrates the clinical significance of
treating spinal cord pathology in CLN1 disease and has shown that
AAV-mediated gene therapy can successfully prevent this when
appropriately targeted. It remains to be seen how effective later
administration of gene therapy would be, and it will be important
to investigate this in future studies. However, our data reveal that
a combination approach of IC/IT-AAV2/9-hPPT1 therapy has
resulted in the greatest extension of life span and preservation of
motor function in Ppt1−/− mice of any preclinical treatment so far
(3, 28). Consistent with the current study, another group recently
presented data in abstract form demonstrating that IT injection of a
self-complementary AAV vector resulted in significant biochemical
and clinical improvements in the Ppt1−/− mouse (52). Our data
strongly suggest that the response could have been much greater if
they had targeted both the brain and spinal cord. Recent clinical
trials in children with other inherited neurological disorders such as
CLN2, CLN6, giant axonal neuropathy, and spinal muscular atro-
phy using direct intracranial or intrathecal injections of AAV vec-
tors (clinicaltrials.gov) have shown that these approaches are safe.
As such, our findings will directly inform strategies for delivering
therapies to children with this invariably fatal disease and other
similar disorders in which spinal pathology may also occur.
Materials and Methods
Human Tissue. Paraffin wax-embedded tissue samples of human thoracic spinal
cord were obtained from the archives of the Department of Pathology, Helsinki
University and the Department of Pathology, Washington University School of
Medicine. These specimens were collected at routine autopsies of CLN1 patients
(n = 1, age of disease onset 1 y, age at death 6 y 10 mo) or neurologically normal
controls (n = 1, age at death 10 y) with informed written consent and the ap-
proval of the Ethical Research Committee of the Institute of Psychiatry, Psychol-
ogy & Neuroscience, King’s College London (approval nos. 223/00 and 181/02).
Animals. Both congenic Ppt1−/− and wild-type mice were maintained on a
C57BL/6J background at Washington University School of Medicine. The colo-
nies were maintained separately through homozygous mating. All procedures
were performed in accordance with NIH guidelines as well as a protocol ap-
proved by the Institutional Animal Care and Use Committee (IACUC) at
Washington University School of Medicine. See SI Materials and Methods for
further details.
Treatment Groups. For the analysis of spinal cord pathology, a sample size of n =
5mice per group for wild-type C57BL/6 mice and Ppt1−/−were used at each time
point of 1, 3, 5, and 7 mo as previously described (14). For the combination
AAV2/9-hPPT1 therapy study, five treatment groups were generated: (i) un-
treated Ppt1−/− mice (n = 22), (ii) AAV2/9-hPPT1 intracranially injected Ppt1−/−
mice (IC-AAV2/9-hPPT1, n = 25), (iii) AAV2/9-hPPT1 intrathecally injected Ppt1−/−
mice (IT-AAV2/9-hPPT1, n = 25), (iv) combination AAV2/9-hPPT1 intracrani-
ally and intrathecally injected Ppt1−/− mice (IC/IT-AAV2/9-hPPT1, n = 25), and
(v) wild-type C57BL/6 (n = 25) mice. We did not include a group of mice treated
with a control AAV vector because we had already included this group in a prior
study, and showed that intracranial injections of an AAV vector expressing GFP

















had no effect on life span or any other parameter measured in Ppt1−/− mice
(12). Longevity and rotarod performance were assessed in the treatment and
control groups (n = 10 mice per group), and randomly selected mice were an-
alyzed at predetermined time points (1, 3, 5, 7, and 9 mo) for biochemical and
histological analyses (n = 3 mice per group). For all studies, experimental and
control animals were randomly assigned identification numbers such that the
person performing the analyses was blind to genotype and treatment, and all
data collected are presented here.
Recombinant AAV Production. The rAAV2/9-hPPT1 vector genome used in this
study is identical to that described and schematically represented previously
(24), and was packaged at the University of North Carolina Vector Core. Viral
titers were adjusted to 1 × 1012 vector genomes (vg)/mL for all injections. See SI
Materials and Methods for further details.
Intracranial and Intrathecal Injections. On postnatal day 1 (PND1) or PND2,
Ppt1−/− pups received intracranial or intrathecal injections with AAV2/9-hPPT1
(1 × 1012 vg/mL) into the anterior cortex, hippocampus, and cerebellum as
previously described (12). For intrathecal injections, PND1 or PND2 Ppt1−/− pups
were injected in the lumbar region as previously described (54, 55). For the
combination treatment, both intracranial and intrathecal injections were per-
formed on the same day in the same pup. See SI Materials and Methods for
further details.
Life Span. Longevity was determined in the treatment and control groups (n =
10 mice per group) by death or euthanasia for humane reasons. A Kaplan–
Meier life span curve was used to measure survival, and significant differences
were determined using a log-rank analysis (P < 0.05).
Rotarod Testing. Motor function and coordination were assessed in the
same treated Ppt1−/− and control mice (n = 10) used for longevity using a
constant-speed (3 rpm) rotarod beginning at 5 mo of age and every 2 mo
thereafter as previously described (12, 18). There was also a 3-d training/
acclimation phase before the first test that allowed for a crude assessment
of learning.
PPT1 Activity and Secondary Enzyme Elevations. Tissue was collected at pre-
determined time points (1, 3, 5, and 7mo). Threemice per treatment groupwere
euthanized via lethal injection (Fatal-Plus; Vortech Pharmaceuticals). PPT1 assays
were performed on brain homogenates as previously described (56). Secondary
elevations of another lysosomal enzyme, β-glucuronidase, were determined as
previously described using a 4-methylumbelliferyl (MU)-β-D-glucuronide fluo-
rometric assay and normalized to total protein (57). See SI Materials and
Methods for further details.
Tissue Processing and Histological Staining. Brain processing and analysis were
performed as previously described (11, 14, 25). Spinal cords were split into
cervical, thoracic, and lumbosacral blocks. Forty-micrometer coronal sections
were cut throughout each brain and spinal cord block and 5-μm-thick sections
were cut from paraffin wax-embedded samples of human thoracic spinal cord.
Sections were then stained for cresyl fast violet (Nissl) as before (11, 13) as a 1 in
6 series of brain sections or a 1 in 24 series of spinal cord sections to reveal
cytoarchitecture. For immunohistochemistry, a 1 in 48 series of free-floating
spinal cord sections from each mouse was stained using a standard immuno-
peroxidase protocol (11, 25) for markers of astrocytes (rabbit anti-GFAP;
1:8,000; Dako) and microglia (rat anti-mouse CD68; 1:2,000; AbD Serotec).
Paraffin wax-embedded human spinal cord tissue sections were similarly
immunostained as previously described (58) for monoclonal mouse anti-CD68
(clone PG-M1; 1:800; Dako).
Histochemical Stain. A histochemical stain for PPT1 activity was performed on
sagittal forebrain sections and transverse sections of spinal cord, as previously
described (35). See SI Materials and Methods for further details.
Visualization of Autofluorescent Storage Material. The accumulation of AFSM
was visualized in unstained sections of tissue and quantified in different regions
of the brain and spinal cord using a previously published method (24). See SI
Materials and Methods for further details.
Stereological Analysis. Counts of neurons in the dorsal and ventral horns of
each hemisection of the spinal cord were performed by a design-based optical
fractionatormethod in a 1 in 48 series of Nissl-stained sections (59) using Stereo
Investigator software (MBF Bioscience) (11). See SI Materials and Methods for
further details.
Thresholding Image Analysis. To analyze the degree of glial activation in the
gray matter of sections stained for GFAP and CD68, a semiautomated
thresholding image analysismethodwas usedwith Image-Pro Premier software
(Media Cybernetics) (11). See SI Materials and Methods for further details.
Cytokine Profile Analysis. Cytokine profiling was performed using an Affy-
metrix multiplex assay through the Center for Human Immunology and Im-
munotherapy Programs (CHiiPS) Immunomonitoring Lab (IML) at Washington
University School of Medicine. Nine analytes (GRO-α, IFN-γ, IL-10, IP-10, MCP-1,
MCP-3, MIP-2, RANTES, and TNF-α) were measured in brain homogenates of
treated animals. See SI Materials and Methods for further details.
Statistical Analysis. All statistical analyseswere performed using Prism software
(GraphPad Software). A two-tailed, unpaired, parametric t test was usedwhere
two groups were compared, and a one-way ANOVA with a Bonferroni post
hoc analysis was used when comparing three or more groups at each time
point. Results were considered statistically significant when P < 0.05. Unless
otherwise stated, statistical comparisons are between the treatment groups
and untreated Ppt1−/−mice. The mean coefficient of error for all stereological
measures was below 0.10 (60), and all measurements were performed blind
to genotype.
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